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Nintedanib-mediated improvement in CT imaging in pulmonary 
fibrosis associated with systemic scleroderma
Abstract
Nintedanib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosine kinases. In patients with idiopathic pulmo-
nary fibrosis and systemic scleroderma-associated interstitial pneumonia (SSc-IP), nintedanib has been effective in suppressing 
the decline in forced vital capacity over time and the onset of acute exacerbation of interstitial pneumonia. Here, we report a 
SSc-IP patient who showed an improvement on CT images following nintedanib treatment. To our knowledge, this is the first 
report of such a case. Although SSc-IP patients are very rare, additional clinical experience and understanding will be required to 
prove the therapeutic benefit of nintedanib in these cases in relation to improved chest images.
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Introduction
Systemic scleroderma-associated interstitial 
pneumonia (SSc-IP) is a collagen disease. It is 
characterized by organ fibrosis due to fibroblast 
proliferation and impaired blood circulation due 
to vascular endothelial cell proliferation in the 
skin and organs, such as the lung and kidney 
[1]. More than half of patients with SSc develop 
interstitial pneumonia (IP) due to inflammation 
and fibrosis in the lung interstitium [2, 3]. Acute 
or subacute progression of IP and pulmonary 
hypertension are serious pathological conditions 
that determine the prognosis of SSc patients [3]. 
The antifibrotic drug nintedanib has been 
shown to suppress the gradual decline in forced 
vital capacity (FVC) and the onset of acute exac-
erbation in idiopathic interstitial pneumonia (IPF) 
patients, and as such, has become one of the most 
reliable drugs for the treatment of IPF [4–6]. Sim-
ilar clinical effects have recently been confirmed 
in patients with SSc-IP in a large-scale clinical 
trial [7]. While nintedanib-mediated suppression 
of progression and advance in prognosis have 
been broadly shown, an improvement on com-
puted tomography (CT) imaging, however, has 
been reported in only a few IPF patients [8–10]. 
To the best of our knowledge, there have been no 
reports of a SSc-IP patient showing improvement 
on CT images. Here, we report on our treatment 
with nintedanib of a patient who exhibited im-
proved CT imaging . Although this type of case 
is extremely rare, reporting it provides valuable 
suggestions for future treatment plans involving 
nintedanib.
Material and methods
A 73-year-old woman was referred to our 
hospital with ground-glass opacities in both 
lower lobes in a chest radiograph taken at mass 
screening. She had had slight dyspnea on exertion 
for several months. She was diagnosed as having 
SSc due to symmetrical thickening, tightening 
and induration of the skin of the fingers and 
the skin proximal to the metacarpophalangeal 
or metatarsophalangeal joints, reticular densi-
ties most pronounced in the basilar areas of the 
lungs on chest radiograph, and the presence of 
anti-centromere antibody. She had no smoking 
habit. The patient was pathologically diagnosed 
with primary biliary cholangitis 25 years ago. 
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Computed tomography taken at the first visit 
showed traction bronchiectasis, bronchial bun-
dle thickening, and ground-glass opacities in the 
lower lobes of both lungs. Blood examination at 
the first visit revealed thrombocytopenia, which 
was refined to idiopathic thrombocytopenia after 
more testing results. 
Therapy with prednisolone and tacrolimus 
was started as a treatment for idiopathic throm-
bocytopenic purpura. The tacrolimus dose was 
2 mg/day, commencing two years before the ini-
tiation of nintedanib. Prednisolone was reduced 
to 5 mg/day four months before the initiation of 
nintedanib, with this dose remaining constant 
ever since. Chest CT images taken 10 months and 
26 months after the initial visit to our hospital 
showed the range of ground-glass opacities ex-
panded and exacerbation was confirmed (Figure 
1A and 1B). 
At that time, nintedanib was reimbursed 
through health insurance in our country. Pa-
tients were thoroughly informed on the benefits 
and adverse effects of nintedanib before starting 
nintedanib treatment. In particular, the dose of 
nintedanib was explained in relation to the re-
sults of the SENSCIS study. Treatment started at 
2 × 100 mg of nintedanib daily. One month after 
the administration of nintedanib, the patient 
noticed an improvement in her dry cough and 
dyspnea, and due to this amelioration in clinical 
symptoms and imaging, desired to continue on 
the same nintedanib dose. As a result, there was 
no dose increase. There were no side effects such 
as loss of appetite or nausea. After commencing 
nintedanib treatment, the patient was asked sev-
eral times about the presence or absence of diar-
rhea, but there were no side effects of diarrhea, 
probably because the patient was taking codeine 
Figure 1. Chest computed tomography (CT) scan 10 months (A) and 26 months (B) after the initial visit to our hospital showed expansion of 
subpleural ground-glass opacities with thickening of vascular bundle in bilateral lower lobes of the lung. Chest CT scan taken 8 months after the 
initiation of nintedanib revealed an improvement of diffuse subpleural ground-glass opacities (C)
A B C
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phosphate as an antitussive. Blood sampling 
examinations including liver function were per-
formed regularly, but no abnormal values due to 
nintedanib were found. Chest CT was performed 
eight months after the start of nintedanib, and 
a regression of ground-glass opacities on chest CT 
scan was confirmed (Figure 1C). An improvement 
on chest CT scan was accompanied by a decrease 
in dry cough and dyspnea on exertion. One year 
after the start of nintedanib, treatment is ongoing.
Discussion
In many pulmonary fibrosis cases, includ-
ing IPF and SSc-IP, fibrosis progresses due to 
an abnormal repair reaction to damage to the 
alveolar epithelium. During this abnormal fi-
brosis, alveolar epithelial cells differentiate into 
fibroblasts and myofibroblasts [11]. Lung fibro-
blast proliferation and migration is stimulated 
by fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF), and fibroblast 
transformation is induced by transforming growth 
factor-b2 [11]. Nintedanib inhibits the action of 
growth factors on tyrosine kinases, mainly FGF, 
VEGF, and platelet derived growth factor (PDGF). 
In a phase III trial in IPF patients, nintedanib was 
effective in suppressing the decline in FVC over 
time and the onset of acute exacerbation of IP 
[4–6]. In SSc-IP patients, a large-scale clinical trial 
has recently been conducted [7], and the clinical 
effects observed in these subjects are similar to 
that observed in IPF patients [12]. There are only 
a few reported cases that show an improvement 
on CT images with nintedanib therapy, and all 
are patients with IPF [8–10].
A recent sub-study analysis of the SENSCIS 
trial examined the effect of nintedanib on HRCT 
markers of fibrosis [13]. It found only nine out 
of 52 SSc-ILD patients treated with nintedanib 
had a notable improvement in fibrotic changes 
on HRCT analysis, and none were classified as 
‘much better’, which was defined by the authors 
as ‘a moderate decrease in honeycombing and/or 
reticulation and/or fibrotic ground-glass opacity; 
a decrease was more than 10%’. According to this 
sub-study analysis, an improvement on CT was 
extremely rare. 
To the best of our knowledge, no similar cases 
of HRCT improvement in SSc-ILD after nintedan-
ib therapy have been published to date. Therefore, 
this is the first SSc-IP case who has showed an 
amelioration in CT images following nintedanib 
treatment, defined by a regression of ground-glass 
opacities and septal thickening on the chest CT 
scan. Our patient also showed an improvement 
in her dry cough as well as dyspnea on effort. 
It is important to consider the possibility that 
mechanisms other than nintedanib might have 
contributed to the patient’s improved CT imag-
es. Firstly, there is the possibility of spontaneous 
changes in SSc cases [14]. Spontaneous changes 
in skin lesions have been reported in SSc patients, 
but there have been no reports of improvement in 
opacities on chest CT images. Secondly, there is 
the potential effect of drugs other than nintedan-
ib. The patient was also receiving corticosteroids 
and tacrolimus, which both commenced three 
years before the initiation of nintedanib. The dose 
of tacrolimus had been constant for two years 
before the initiation of nintedanib. The dose of 
prednisolone was reduced four months before the 
introduction of nintedanib, and had not changed 
since. Chest CT scans were taken several times 
during the administration of these drugs, which 
showed a gradual exacerbation of ground-glass 
opacities over time, but no improvement. There-
fore, the possibility of these drugs contributing 
to the improvement on CT images is low, and it 
was instead considered to be due to the effect of 
nintedanib.
Nintedanib has been reported to have gastro-
intestinal adverse effects (AEs) such as appetite 
loss, nausea and liver dysfunction [4–6]. In our 
patient, frequent examination did not find any 
severe AEs to prevent continuing treatment. In 
addition to CT images, therapeutic effects in SSc-
IP patients can be observed in respiratory func-
tion and pathological evaluations. On exertion, 
there was no decrease in oxygen saturation, and 
an improvement in subjective symptoms such as 
dry cough and dyspnea was observed. However, 
as the patient did not wish to be examined, there 
were no assessment on pulmonary function and 
histopathological evaluation.
This case report has some limitations. One of 
them is the lack of pathological examination. The 
pattern shown on CT scans was probably non-
specific interstitial pneumonia, and this pattern 
might be reversible, if cellular component was 
present. Evaluation of tissue specimens obtained 
by transbronchial lung biopsy (TBLB) would be 
useful. If performing TBLB was difficult, analysis 
of bronchoalveolar lavage fluid would be helpful 
to understand why these changes were reversible. 
The other serious disadvantage was the lack of 
lung function data before and after treatment. 
Results of pulmonary function tests, including 
spirometry and diffusing capacity for carbon 
monoxide, and six-minute walk test before and 
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after eight months of therapy with nintedanib, 
would be important to confirm a functional im-
provement corresponding to a CT amelioration 
of fibrotic changes. However, due to patient’s 
refusal to perform any of these tests, as well as 
the circumstances associated with the outbreak 
of coronavirus disease in 2019 (COVID-19), they 
were not performed.
Conclusions
In conclusion, our observation suggests that 
nintedanib contributes to reducing regression of 
ground-glass opacities in SSc-IP patients. This 
indicates these rare patients could be expected to 
exhibit improved CT images with nintedanib ther-
apy. It remains to be elucidated what characteris-
tics of SSc-IP patients are related to improvement 
of the CT image, and the precise mechanism of 
action of nintedanib noting its inhibitory action 
on growth factors such as FGF, VEGF, and PDGF. 
Although careful consideration of side effects is 
required, if nintedanib can improve CT images 
in addition to the previously confirmed effects, 
it would be a desirable treatment option for SSc-
IP patients. Additional clinical experience and 
knowledge will be required to prove our obser-
vation of the therapeutic effect of nintedanib on 
improving chest images.
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